Connect with us

Art & Science

Alzheimer: China approves the world’s first algae-based drug

From China a new drug based on an alga for the treatment of Alzheimer’s disease. Find out more about the study and its achievements



Alzheimer China approves the world's first algae-based drug

An important turning point in Alzheimer’s treatment. China has given the go-ahead to the first drug that could give new possibilities to those suffering from this pathology.

As estimated by the World Health Organization, in 2050 there will be as many as 150 million Alzheimer’s patients and therefore it is important to intensify the search for new treatments.

The new drug being discussed is based on the seaweed extract as the main ingredient. According to what the NMPA declared the new drug would have received the ok.
The research team, led by Geng Meiyu of the Shanghai Institute, started looking for possible connections and identified a specific sugar in the algae that could play a very important role. The algae drug could significantly improve the symptoms of Alzheimer’s disease.

In 22 years of research, the team led by Geng Meiyu has developed the GV-971 molecule based on a study involving 1.199 people demonstrating an important cognitive improvement in patients with mild to moderate Alzheimer’s.

The study showed that during the progression of Alzheimer’s disease the composition of the intestinal microbiota that leads to the accumulation of phenylalanine and isoleucine is altered, which in turn stimulates the proliferation of Th1 pro-inflammatory cells. These then contribute to the inflammation associated with the disease.

The GV-971 molecule suppresses intestinal dysbiosis and thus the accumulation of phenylalanine and isoleucine by reversing cognitive deterioration.

Therefore, we can deduce the importance of acting on the intestinal microbiota to combat the progression of Alzheimer’s disease.

Interesting videos

Copyright © 2019 - FidelityHouse International SA, Via Guido Calgari 2 - 6900 Lugano, Switzerland - VAT number: CHE-464.450.684